Analysis of the Breast Cancer Drug Market by SERM-based, Aromatase Inhibitors-based, Biologic Response Modifiers-based, and Other Hormonal Therapies-based
Increasing Clinical Trials and Research Programs for New Cancer Drugs Development to Accelerate the Growth of the Breast Cancer Drug Market
The global breast cancer drug market size is expected to be valued at US$ 10,733.1 million in 2023. The increasing prevalence of the disease, along with evolving novel therapies, are some of the key factors likely to drive the market. Early detection of breast cancer is key to the effective management of the disease. The overall demand for breast cancer drugs is projected to grow at a CAGR of 1.1% between 2023 and 2033, totaling around 12,012.1 million by 2033.
Data Points
Key Statistics
Breast Cancer Drug Market Value 2023
US$ 10,733.1 million
Breast Cancer Drug Market Projected Value (2033)
US$ 12,012.1 million
Breast Cancer Drug Market CAGR (2023 to 2033)
1.1%
Breast cancer is the most common cancer in women worldwide. From the recent reports on cancer, 1.7 million breast cancer cases have been recorded in a year. Women in developed countries such as the USA, United Kingdom, and Australia have a higher risk than those in developing countries.
Many factors are responsible for developing breast cancer, including lifestyle, age, heredity, and genetic mutations (abnormal changes). Scientists are working on finding how gene variations are affecting breast cancer and studying new methods for imaging methods to evaluate abnormalities at early stages.
Newer drug valuation is expected to be upward as it is difficult to treat advanced breast cancers. WHO has a global action plan on non-communicable diseases endorsed by many countries, which is a part to reduce the growing cases and address women's cancer.
Over the past few decades, recent advancements and new drug developments have fuelled the breast cancer drug market. In Oct 2021, the FDA approved a new drug called abemaciclib - Verzenio- for one type of breast cancer. This drug is approved for patients with HR+, HER2-early breast cancer, which makes up 70% of all breast cancers. The drug was already approved for advanced or metastatic breast cancer.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Breast Cancer Drug Demand Analysis (2018 to 2022) Vs Market Outlook (2023 to 2033)
The global demand for Breast Cancer drugs is projected to increase at a CAGR of 1.1% during the forecast period between 2023 and 2033, reaching a total of US$ 12,012.1 million in 2033, according to a report from Future Market Insights (FMI). From 2017 to 2021, sales witnessed significant growth, registering a CAGR of 1.3%.
As per a recent analysis by the American Cancer Society, in the USA, 266,120 new cases were diagnosed in women in 2018. Furthermore, aging is considered one of the greatest risk factors. According to Cancer Treatment Centers of America, women above 60 are more likely to be diagnosed, and only about 10% to 15% of cases occur in women younger than 45. The rising occurrence of cancer cases has burgeoned the demand for breast cancer drugs in recent years.
Over the coming years, the soaring emphasis on the development of more effective treatment procedures and advanced drugs is projected to foster the breast cancer drug market.
Which Drivers Underpin Breast Cancer Drug Industry Expansion?
The breast cancer drug market is scaling up, and the research towards improved chemotherapy drugs and targeted therapies are the major concerns of all medical centers worldwide. According to International Agency for Research on Cancer (IARC), published by the World Health Organization (WHO) in 2021, breast cancer ranked as the fifth leading cause of death in women, accounting for 627,000 deaths every year.
Several governments and non-profit organizations are working incessantly and organizing programs to increase awareness and provide financial aid to patients diagnosed with breast cancer. For instance, the sister study is taken by the National Institute of Environmental Health Sciences to help women with early diagnosis by considering all the possible factors that affect breast cancer.
New generation treatments and bio-similar versions, Physical inactivity, environmental factors, lifestyle, and hormonal changes during aging pump in the breast cancer drug market.
Find your sweet spots for generating winning opportunities in this market.
Which Factors are limiting the Growth of the Breast Cancer Drug Market?
According to the recently published report by Future Market Insights, the breast cancer drug market is estimated to progress in the future. Still, the stringent rules and regulations, prolonged therapies degrading the health, shortage of accessible medical attention, and healthcare literacy are some aspects that may restrain the market expansion throughout the projection period.
Despite the positive outlook, side effects associated with breast cancer drugs and their expensive nature, may impede the remuneration scope of the industry during the analysis timeframe.
Region-wise Insights
Will North America Hold a Significant Position in the Global Breast Cancer Drug Market?
Regarding geographic divisions, North America is expected to account for a 52.1% share of the breast cancer drug market in 2023. According to Future Market Insights analysis, the region is estimated to grow significantly over the forecast period. This market growth is attributed to the increasing number of cases of breast cancer and the lifestyle followed by women. The United States and Canada are the prominent shareholders in the regional revenue generation, backed by their robust healthcare infrastructure and high investments in clinical trials.
Supportive reimbursement policies are likely to positively impact the market's growth trajectory in the forthcoming years. Moreover, to minimize the pervasiveness of the disease, USA President Joe Biden, in 2022, relaunched a program dubbed 'Moonshot' to accelerate cancer research, which was first introduced in 2017. The program raised funding of USD 1.8 million in the last seven years and aims to reduce cancer fatality rates by a staggering 50% over the next 25 years.
Innovative and progressive treatment procedures like cancer vaccinations are currently being researched in congruence with chemotherapy and immunotherapy, as it has been detected that cancer vaccinations have a greater success ratio in killing tumor cells. Some vaccinations may be customizable, while others cover a broader spectrum.
How Will the Growth of the European Breast Cancer Drug Market unfold?
Based on Future Market Insight's recent analysis, Europe is expected to account for nearly 26.7% of the breast cancer drug market in 2023. European nations like France, Germany, and Italy are anticipated to hold vital opportunities and generate the highest revenue share in the breast cancer drugs market. There is a robust plan as Patient Support Programs, and campaigns are organized in various countries to spread awareness about breast cancer and early diagnosis and treatment.
AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens.
Enhertu is a specifically engineered HER2-directed antibody-drug conjugate (ADC) being jointly developed and commercialized by AstraZeneca and Daiichi Sankyo. Approvals of new treatment procedures and soaring investments in Research and Development by prominent players have fuelled the revenue generation of the European market.
How is the Asia Pacific bolstering the demand for breast cancer drugs?
According to Future Market Insights, Asia Pacific is one of the most significant regions based on the Breast Cancer Drug market development and is estimated to witness impressive growth throughout the forecast period. Rapid growth in global demand for drugs has compelled prominent drug manufacturers to set up facilities for manufacturing Research and Development in this region.
Initiatives commenced by several organizations to create awareness, educate people, and raise funds for the disease are projected to propel regional growth. For instance, Wacoal Corp. runs the Pink Ribbon Fitting Campaign and donates funds to the Japan Society of Breast Health, J. POSH, and Japan Cancer Society (Smile Fund) on behalf of customers.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need and save 40%!
Category-wise Insights
By type, Which Breast Cancer Drug Category will remain Prominent?
The global breast cancer drug market is bifurcated into the drug class, distribution channels, and regions. Breast cancer is the most commonly diagnosed cancer in women worldwide and also is one of the leading causes of death. Based on the disease indication, HER2-positive treatment is likely to remain the key revenue generator over the forecast period.
The increasing occurrence of HER2-positive breast cancer is the foremost aspect attributed to the growth of this segment. According to a recently published article by F. Hoffman La Roche Ltd, it was assessed that nearly one in five women diagnosed with breast tumors would have HER2-positive cancer. Furthermore, rapidly growing demand from emerging markets such as the Asia Pacific and Latin America is expected to further drive growth during the forecast period.
CDK 4/6 inhibitor is anticipated to be the fastest-growing segment throughout the forecast period. These drugs are likely to improve the survival rate in patients with metastatic breast cancer. Moreover, the commercialization of novel drugs, such as Kisqali by Novartis AG and Verzenio by Eli Lilly and Company, is expected to propel the segment's growth in the forthcoming years.
The Start-up Ecosystem: How Key Players are Opening Frontiers for Future Growth?
Founded in 2014, ScreenPoint provides AI-based medical image analysis systems. The company's flagship product, Transpara, is based on the automated analysis of digital mammograms and breast tomosynthesis data for the early detection of breast cancer. Transpara enables decision support for soft tissue lesions, CAD, and exam selection for pre-screening. The company is based in the Netherlands and has collected total funding worth US$ 33 million.
Launched in 2014, iSono Health is a developer of a wearable device for early breast cancer detection. The company has developed an automated, portable, and wearable ultrasound imaging platform by using 3D ultrasound technology along with the machine learning algorithm that enables users to scan and capture images of the breast and further share them with the radiologist for analysis and report generation. The company is headquartered in San Fransisco, USA, and received overall funding of 120k Billion from Y Combinator, Plug and Play Tech Center, Gershon Capital, and 5 Other Investors.
Competitive Landscape What are the Leading Players in the Breast Cancer Drug Market Up to?
In August 2021, Pfizer Inc. and Trillium Therapeutics Inc. entered into a definitive agreement under which Pfizer will acquire Trillium, a clinical-stage immuno-oncology company developing innovative therapies for the treatment of cancer. Under the terms of the agreement, Pfizer will acquire all outstanding shares of Trillium not already owned by Pfizer for an implied equity value of $2.26 billion, or $18.50 per share, in cash.
In June 2022, Novartis announced new overall survival (OS) and quality of life (QoL) analyses which evaluated Kisqali® (ribociclib) plus endocrine therapy for patients with hormone receptor-positive/human epidermal growth factor receptor-negative (HR+/HER2-) advanced or metastatic breast cancer.
Report Scope
Report Attribute
Details
Growth Rate
CAGR of 1.1% from 2023 to 2033
Market Value in 2023
US$ 10,733.1 million
Market Value in 2033
US$ 12,012.1 million
Base Year for Estimation
2021
Historical Data
2018 to 2022
Forecast Period
2023 to 2033
Quantitative Units
Revenue in US$ million and CAGR from 2023 to 2033
Report Coverage
Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis
Segments Covered
Drug Class
Distribution Channel
Region
Regions Covered
North America
Latin America
Europe
Asia Pacific
Middle East and Africa
Key Countries Profiled
United States of America
Canada
Brazil
Mexico
Germany
United Kingdom
France
Spain
Italy
China
Japan
South Korea
GCC Countries
South Africa
Israel
Key Companies Profiled
F. Hoffmann-La Roche Ltd
Pfizer Inc.
AstraZeneca
Novartis International AG
Achieve Life Science
Bristol-Myers Squibb
Eisai Co. Ltd
AbbVie
Eli Lilly & Company
Celgene Corporation
Merck & Co.
Amgen Plc.
Celldex Therapeutics
Biocon Genzyme Corporation
Key Segments Covered in the Breast Cancer Drug Industry Analysis
What is the Global Market Size for Breast Cancer Drugs?
Worldwide demand in 2023 can accrue almost US$ 10,733.1 million.
What is the Forecast for Breast Cancer Drug Sales Worldwide?
The global sales of such drugs is forecasted to generate US$ 12,012.1 million by 2033.
What is the Total Share of Breast Cancer Drug Sales in North America?
The regional market is forecasted to account for 52.1% of the global market in 2023.
Which Type is the Leading Segment in the Global Breast Cancer Drugs?
Drugs for HER2-positive treatment is the leading segment.
Who are the Leading Players in the Breast Cancer Drug Market?
F. Hoffmann, Pfizer, and AstraZeneca are the top manufacturers.
Table of Content
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033
5.3.1. SERM (Selective Estrogen-Receptor Modulators)-based
5.3.2. Aromatase Inhibitors-based
5.3.3. Biologic Response Modifiers-based
5.3.4. Other Hormonal Therapies-based
5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033
6.3.1. Hospital Pharmacies
6.3.2. Pharmacies
6.3.3. Drug Stores
6.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
7.1. Introduction
7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
7.3.1. North America
7.3.2. Latin America
7.3.3. Western Europe
7.3.4. Eastern Europe
7.3.5. South Asia and Pacific
7.3.6. East Asia
7.3.7. Middle East and Africa
7.4. Market Attractiveness Analysis By Region
8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
8.2.1. By Country
8.2.1.1. USA
8.2.1.2. Canada
8.2.2. By Drug Class
8.2.3. By Distribution Channel
8.3. Market Attractiveness Analysis
8.3.1. By Country
8.3.2. By Drug Class
8.3.3. By Distribution Channel
8.4. Key Takeaways
9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. Brazil
9.2.1.2. Mexico
9.2.1.3. Rest of Latin America
9.2.2. By Drug Class
9.2.3. By Distribution Channel
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Drug Class
9.3.3. By Distribution Channel
9.4. Key Takeaways
10. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Germany
10.2.1.2. UK
10.2.1.3. France
10.2.1.4. Spain
10.2.1.5. Italy
10.2.1.6. Rest of Western Europe
10.2.2. By Drug Class
10.2.3. By Distribution Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Drug Class
10.3.3. By Distribution Channel
10.4. Key Takeaways
11. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Poland
11.2.1.2. Russia
11.2.1.3. Czech Republic
11.2.1.4. Romania
11.2.1.5. Rest of Eastern Europe
11.2.2. By Drug Class
11.2.3. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Drug Class
11.3.3. By Distribution Channel
11.4. Key Takeaways
12. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. India
12.2.1.2. Bangladesh
12.2.1.3. Australia
12.2.1.4. New Zealand
12.2.1.5. Rest of South Asia and Pacific
12.2.2. By Drug Class
12.2.3. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Drug Class
12.3.3. By Distribution Channel
12.4. Key Takeaways
13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. China
13.2.1.2. Japan
13.2.1.3. South Korea
13.2.2. By Drug Class
13.2.3. By Distribution Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Drug Class
13.3.3. By Distribution Channel
13.4. Key Takeaways
14. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. GCC Countries
14.2.1.2. South Africa
14.2.1.3. Israel
14.2.1.4. Rest of MEA
14.2.2. By Drug Class
14.2.3. By Distribution Channel
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Drug Class
14.3.3. By Distribution Channel
14.4. Key Takeaways
15. Key Countries Market Analysis
15.1. USA
15.1.1. Pricing Analysis
15.1.2. Market Share Analysis, 2022
15.1.2.1. By Drug Class
15.1.2.2. By Distribution Channel
15.2. Canada
15.2.1. Pricing Analysis
15.2.2. Market Share Analysis, 2022
15.2.2.1. By Drug Class
15.2.2.2. By Distribution Channel
15.3. Brazil
15.3.1. Pricing Analysis
15.3.2. Market Share Analysis, 2022
15.3.2.1. By Drug Class
15.3.2.2. By Distribution Channel
15.4. Mexico
15.4.1. Pricing Analysis
15.4.2. Market Share Analysis, 2022
15.4.2.1. By Drug Class
15.4.2.2. By Distribution Channel
15.5. Germany
15.5.1. Pricing Analysis
15.5.2. Market Share Analysis, 2022
15.5.2.1. By Drug Class
15.5.2.2. By Distribution Channel
15.6. UK
15.6.1. Pricing Analysis
15.6.2. Market Share Analysis, 2022
15.6.2.1. By Drug Class
15.6.2.2. By Distribution Channel
15.7. France
15.7.1. Pricing Analysis
15.7.2. Market Share Analysis, 2022
15.7.2.1. By Drug Class
15.7.2.2. By Distribution Channel
15.8. Spain
15.8.1. Pricing Analysis
15.8.2. Market Share Analysis, 2022
15.8.2.1. By Drug Class
15.8.2.2. By Distribution Channel
15.9. Italy
15.9.1. Pricing Analysis
15.9.2. Market Share Analysis, 2022
15.9.2.1. By Drug Class
15.9.2.2. By Distribution Channel
15.10. Poland
15.10.1. Pricing Analysis
15.10.2. Market Share Analysis, 2022
15.10.2.1. By Drug Class
15.10.2.2. By Distribution Channel
15.11. Russia
15.11.1. Pricing Analysis
15.11.2. Market Share Analysis, 2022
15.11.2.1. By Drug Class
15.11.2.2. By Distribution Channel
15.12. Czech Republic
15.12.1. Pricing Analysis
15.12.2. Market Share Analysis, 2022
15.12.2.1. By Drug Class
15.12.2.2. By Distribution Channel
15.13. Romania
15.13.1. Pricing Analysis
15.13.2. Market Share Analysis, 2022
15.13.2.1. By Drug Class
15.13.2.2. By Distribution Channel
15.14. India
15.14.1. Pricing Analysis
15.14.2. Market Share Analysis, 2022
15.14.2.1. By Drug Class
15.14.2.2. By Distribution Channel
15.15. Bangladesh
15.15.1. Pricing Analysis
15.15.2. Market Share Analysis, 2022
15.15.2.1. By Drug Class
15.15.2.2. By Distribution Channel
15.16. Australia
15.16.1. Pricing Analysis
15.16.2. Market Share Analysis, 2022
15.16.2.1. By Drug Class
15.16.2.2. By Distribution Channel
15.17. New Zealand
15.17.1. Pricing Analysis
15.17.2. Market Share Analysis, 2022
15.17.2.1. By Drug Class
15.17.2.2. By Distribution Channel
15.18. China
15.18.1. Pricing Analysis
15.18.2. Market Share Analysis, 2022
15.18.2.1. By Drug Class
15.18.2.2. By Distribution Channel
15.19. Japan
15.19.1. Pricing Analysis
15.19.2. Market Share Analysis, 2022
15.19.2.1. By Drug Class
15.19.2.2. By Distribution Channel
15.20. South Korea
15.20.1. Pricing Analysis
15.20.2. Market Share Analysis, 2022
15.20.2.1. By Drug Class
15.20.2.2. By Distribution Channel
15.21. GCC Countries
15.21.1. Pricing Analysis
15.21.2. Market Share Analysis, 2022
15.21.2.1. By Drug Class
15.21.2.2. By Distribution Channel
15.22. South Africa
15.22.1. Pricing Analysis
15.22.2. Market Share Analysis, 2022
15.22.2.1. By Drug Class
15.22.2.2. By Distribution Channel
15.23. Israel
15.23.1. Pricing Analysis
15.23.2. Market Share Analysis, 2022
15.23.2.1. By Drug Class
15.23.2.2. By Distribution Channel
16. Market Structure Analysis
16.1. Competition Dashboard
16.2. Competition Benchmarking
16.3. Market Share Analysis of Top Players
16.3.1. By Regional
16.3.2. By Drug Class
16.3.3. By Distribution Channel
17. Competition Analysis
17.1. Competition Deep Dive
17.1.1. F. Hoffmann-La Roche Ltd
17.1.1.1. Overview
17.1.1.2. Product Portfolio
17.1.1.3. Profitability by Market Segments
17.1.1.4. Sales Footprint
17.1.1.5. Strategy Overview
17.1.1.5.1. Marketing Strategy
17.1.2. Pfizer Inc.
17.1.2.1. Overview
17.1.2.2. Product Portfolio
17.1.2.3. Profitability by Market Segments
17.1.2.4. Sales Footprint
17.1.2.5. Strategy Overview
17.1.2.5.1. Marketing Strategy
17.1.3. AstraZeneca
17.1.3.1. Overview
17.1.3.2. Product Portfolio
17.1.3.3. Profitability by Market Segments
17.1.3.4. Sales Footprint
17.1.3.5. Strategy Overview
17.1.3.5.1. Marketing Strategy
17.1.4. Novartis International AG
17.1.4.1. Overview
17.1.4.2. Product Portfolio
17.1.4.3. Profitability by Market Segments
17.1.4.4. Sales Footprint
17.1.4.5. Strategy Overview
17.1.4.5.1. Marketing Strategy
17.1.5. Achieve Life Science
17.1.5.1. Overview
17.1.5.2. Product Portfolio
17.1.5.3. Profitability by Market Segments
17.1.5.4. Sales Footprint
17.1.5.5. Strategy Overview
17.1.5.5.1. Marketing Strategy
17.1.6. Bristol-Myers Squibb
17.1.6.1. Overview
17.1.6.2. Product Portfolio
17.1.6.3. Profitability by Market Segments
17.1.6.4. Sales Footprint
17.1.6.5. Strategy Overview
17.1.6.5.1. Marketing Strategy
17.1.7. Eisai Co. Ltd
17.1.7.1. Overview
17.1.7.2. Product Portfolio
17.1.7.3. Profitability by Market Segments
17.1.7.4. Sales Footprint
17.1.7.5. Strategy Overview
17.1.7.5.1. Marketing Strategy
17.1.8. AbbVie
17.1.8.1. Overview
17.1.8.2. Product Portfolio
17.1.8.3. Profitability by Market Segments
17.1.8.4. Sales Footprint
17.1.8.5. Strategy Overview
17.1.8.5.1. Marketing Strategy
17.1.9. Eli Lilly & Company
17.1.9.1. Overview
17.1.9.2. Product Portfolio
17.1.9.3. Profitability by Market Segments
17.1.9.4. Sales Footprint
17.1.9.5. Strategy Overview
17.1.9.5.1. Marketing Strategy
17.1.10. Celgene Corporation
17.1.10.1. Overview
17.1.10.2. Product Portfolio
17.1.10.3. Profitability by Market Segments
17.1.10.4. Sales Footprint
17.1.10.5. Strategy Overview
17.1.10.5.1. Marketing Strategy
17.1.11. Merck & Co.
17.1.11.1. Overview
17.1.11.2. Product Portfolio
17.1.11.3. Profitability by Market Segments
17.1.11.4. Sales Footprint
17.1.11.5. Strategy Overview
17.1.11.5.1. Marketing Strategy
17.1.12. Amgen Plc.
17.1.12.1. Overview
17.1.12.2. Product Portfolio
17.1.12.3. Profitability by Market Segments
17.1.12.4. Sales Footprint
17.1.12.5. Strategy Overview
17.1.12.5.1. Marketing Strategy
17.1.13. Celldex Therapeutics
17.1.13.1. Overview
17.1.13.2. Product Portfolio
17.1.13.3. Profitability by Market Segments
17.1.13.4. Sales Footprint
17.1.13.5. Strategy Overview
17.1.13.5.1. Marketing Strategy
17.1.14. Biocon Genzyme Corporation
17.1.14.1. Overview
17.1.14.2. Product Portfolio
17.1.14.3. Profitability by Market Segments
17.1.14.4. Sales Footprint
17.1.14.5. Strategy Overview
17.1.14.5.1. Marketing Strategy
18. Assumptions & Acronyms Used19. Research Methodology
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
List of Tables
Table 1: Global Market Value (US$ Million) Forecast by Region, 2018 to 2033
Table 2: Global Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 3: Global Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 4: North America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 5: North America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 6: North America Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 7: Latin America Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 8: Latin America Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 9: Latin America Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 10: Western Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 11: Western Europe Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 12: Western Europe Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 13: Eastern Europe Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 14: Eastern Europe Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 15: Eastern Europe Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 16: South Asia and Pacific Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 17: South Asia and Pacific Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 18: South Asia and Pacific Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 19: East Asia Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 20: East Asia Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 21: East Asia Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Table 22: Middle East and Africa Market Value (US$ Million) Forecast by Country, 2018 to 2033
Table 23: Middle East and Africa Market Value (US$ Million) Forecast by Drug Class, 2018 to 2033
Table 24: Middle East and Africa Market Value (US$ Million) Forecast by Distribution Channel, 2018 to 2033
Find your sweet spots for generating winning opportunities in this market.
List of Charts
Figure 1: Global Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 2: Global Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 3: Global Market Value (US$ Million) by Region, 2023 to 2033
Figure 4: Global Market Value (US$ Million) Analysis by Region, 2018 to 2033
Figure 5: Global Market Value Share (%) and BPS Analysis by Region, 2023 to 2033
Figure 6: Global Market Y-o-Y Growth (%) Projections by Region, 2023 to 2033
Figure 7: Global Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 8: Global Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 9: Global Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 10: Global Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 11: Global Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 12: Global Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 13: Global Market Attractiveness by Drug Class, 2023 to 2033
Figure 14: Global Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 15: Global Market Attractiveness by Region, 2023 to 2033
Figure 16: North America Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 17: North America Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 18: North America Market Value (US$ Million) by Country, 2023 to 2033
Figure 19: North America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 20: North America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 21: North America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 22: North America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 23: North America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 24: North America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 25: North America Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 26: North America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 27: North America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 28: North America Market Attractiveness by Drug Class, 2023 to 2033
Figure 29: North America Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 30: North America Market Attractiveness by Country, 2023 to 2033
Figure 31: Latin America Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 32: Latin America Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 33: Latin America Market Value (US$ Million) by Country, 2023 to 2033
Figure 34: Latin America Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 35: Latin America Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 36: Latin America Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 37: Latin America Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 38: Latin America Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 39: Latin America Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 40: Latin America Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 41: Latin America Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 42: Latin America Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 43: Latin America Market Attractiveness by Drug Class, 2023 to 2033
Figure 44: Latin America Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 45: Latin America Market Attractiveness by Country, 2023 to 2033
Figure 46: Western Europe Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 47: Western Europe Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 48: Western Europe Market Value (US$ Million) by Country, 2023 to 2033
Figure 49: Western Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 50: Western Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 51: Western Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 52: Western Europe Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 53: Western Europe Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 54: Western Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 55: Western Europe Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 56: Western Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 57: Western Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 58: Western Europe Market Attractiveness by Drug Class, 2023 to 2033
Figure 59: Western Europe Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 60: Western Europe Market Attractiveness by Country, 2023 to 2033
Figure 61: Eastern Europe Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 62: Eastern Europe Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 63: Eastern Europe Market Value (US$ Million) by Country, 2023 to 2033
Figure 64: Eastern Europe Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 65: Eastern Europe Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 66: Eastern Europe Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 67: Eastern Europe Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 68: Eastern Europe Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 69: Eastern Europe Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 70: Eastern Europe Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 71: Eastern Europe Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 72: Eastern Europe Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 73: Eastern Europe Market Attractiveness by Drug Class, 2023 to 2033
Figure 74: Eastern Europe Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 75: Eastern Europe Market Attractiveness by Country, 2023 to 2033
Figure 76: South Asia and Pacific Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 77: South Asia and Pacific Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 78: South Asia and Pacific Market Value (US$ Million) by Country, 2023 to 2033
Figure 79: South Asia and Pacific Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 80: South Asia and Pacific Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 81: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 82: South Asia and Pacific Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 83: South Asia and Pacific Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 84: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 85: South Asia and Pacific Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 86: South Asia and Pacific Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 87: South Asia and Pacific Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 88: South Asia and Pacific Market Attractiveness by Drug Class, 2023 to 2033
Figure 89: South Asia and Pacific Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 90: South Asia and Pacific Market Attractiveness by Country, 2023 to 2033
Figure 91: East Asia Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 92: East Asia Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 93: East Asia Market Value (US$ Million) by Country, 2023 to 2033
Figure 94: East Asia Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 95: East Asia Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 96: East Asia Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 97: East Asia Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 98: East Asia Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 99: East Asia Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 100: East Asia Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 101: East Asia Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 102: East Asia Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 103: East Asia Market Attractiveness by Drug Class, 2023 to 2033
Figure 104: East Asia Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 105: East Asia Market Attractiveness by Country, 2023 to 2033
Figure 106: Middle East and Africa Market Value (US$ Million) by Drug Class, 2023 to 2033
Figure 107: Middle East and Africa Market Value (US$ Million) by Distribution Channel, 2023 to 2033
Figure 108: Middle East and Africa Market Value (US$ Million) by Country, 2023 to 2033
Figure 109: Middle East and Africa Market Value (US$ Million) Analysis by Country, 2018 to 2033
Figure 110: Middle East and Africa Market Value Share (%) and BPS Analysis by Country, 2023 to 2033
Figure 111: Middle East and Africa Market Y-o-Y Growth (%) Projections by Country, 2023 to 2033
Figure 112: Middle East and Africa Market Value (US$ Million) Analysis by Drug Class, 2018 to 2033
Figure 113: Middle East and Africa Market Value Share (%) and BPS Analysis by Drug Class, 2023 to 2033
Figure 114: Middle East and Africa Market Y-o-Y Growth (%) Projections by Drug Class, 2023 to 2033
Figure 115: Middle East and Africa Market Value (US$ Million) Analysis by Distribution Channel, 2018 to 2033
Figure 116: Middle East and Africa Market Value Share (%) and BPS Analysis by Distribution Channel, 2023 to 2033
Figure 117: Middle East and Africa Market Y-o-Y Growth (%) Projections by Distribution Channel, 2023 to 2033
Figure 118: Middle East and Africa Market Attractiveness by Drug Class, 2023 to 2033
Figure 119: Middle East and Africa Market Attractiveness by Distribution Channel, 2023 to 2033
Figure 120: Middle East and Africa Market Attractiveness by Country, 2023 to 2033
